Sofusa anti-TNF is our product candidate for the treatment of Rheumatoid Arthritis (RA)

• RA (1.5+ million people are affected per year (.6% in the US population) is an autoimmune disease in which the body’s immune system mistakenly attacks the joints.  This creates inflammation that causes the tissue that lines the inside of joints to thicken, resulting in swelling and pain
• Women are 2 to 3 times more likely to be affected as men
• Affects the joints of hands, feet, wrists, elbows, knees and ankles.  It is usually symmetrical
• Because of the progressive nature of the RA, approximately 20% to 70% of individuals who were working at the inception of their RA were disabled after 7 – 10 years
• Lymphatic delivery of anti-TNF treatment has potential to improve clinical response, reduce the amount of immune suppressive drug needed, or both